1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Multiple System Atrophy (MSA) - Epidemiology Forecast to 2030

Multiple System Atrophy (MSA) - Epidemiology Forecast to 2030

  • January 2021
  • 80 pages
  • ID: 6010470
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Multiple System Atrophy (MSA)-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the MSA, historical and forecasted epidemiology as well as the MSA trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Multiple System Atrophy (MSA) Disease Understanding
Multiple System Atrophy (MSA), formerly known as Shy-Drager Syndrome, is a rare, degenerative neurological disorder affecting the body’s involuntary (autonomic) functions, including blood pressure, breathing, bladder function, and motor control. The term multiple system atrophy was first introduced in the medical literature in 1969. It encompasses three presentations of a single disease formerly thought to be separate disorders, specifically Shy-Drager syndrome (which emphasized autonomic dysfunction), striatonigral degeneration (which emphasized parkinsonian symptoms), and sporadic olivopontocerebellar atrophy (which emphasized cerebellar symptoms).
MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P) and MSA-predominant cerebellar ataxia (MSA-C). A patient diagnosed with MSA-P may over time appear to have MSA-C and vice versa, so these categorizations are not always set in stone.

Multiple System Atrophy (MSA) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA scenario of MSA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Multiple System Atrophy (MSA) Detailed Epidemiology Segmentation
• In 2017, the prevalent cases of MSA in the 7MM was 41,033.
• The diagnosed patient pool in the 7MM comprised of 22,568 patients in 2017.
• In the case of the United States, the prevalent population of MSA was 14,496 in 2017.
• It has been observed that males accounted for more prevalent cases of MSA than females. In 2017, out of the total diagnosed prevalent cases of MSA, 4,784 cases accounted for males and 3,189 for females, in the US.
• In the epidemiology model of MSA, for age-specific cases, the categorization is done in the following age group, i.e., 30–39 Years, 40–49 Years, 50–59 Years, 60–79 Years, and 80+ Years. In the US, the majority of the cases are observed in the age group, 50–59 Years (51.52%), whereas, in EU-5, and Japan, the majority of the cases are observed in the age group 60–79 Years.
• MSA is broken down into two main subtypes based on the predominant symptom: MSA-predominant Parkinsonism (MSA-P), and MSA-predominant cerebellar ataxia (MSA-C).
• In the US and EU-5 countries, MSA-P type is more prevalent as compared to MSA-C type, but in Japan, the trend is the opposite. In Japan, MSA-C type (70%) is more prevalent as compared to MSA-P (30%).
• In the EU5, the highest prevalent cases were reported to be in Italy followed by Germany, and the United Kingdom whereas the lowest prevalence rates were reported in Spain during the period of 2017–2030.
• Japan was reported to have 10,360 prevalent cases of MSA in 2017.

Scope of the Report
• The report covers the descriptive overview of MSA, explaining its signs and symptoms, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of MSA.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of MSA, Diagnosed Prevalent Patient Population of MSA, Gender-specific Diagnosed Prevalent Population of MSA, Age-specific Diagnosed Prevalent Population of MSA, and Type-specific Diagnosed Prevalent Population of MSA.

Report Highlights
• 11-Year Forecast of MSA
• 7MM Coverage
• Total Prevalent Cases of MSA
• Diagnosed Prevalent Patient Population of MSA
• Gender-specific Diagnosed Prevalent Population of MSA
• Age-specific Diagnosed Prevalent Population of MSA
• Type-specific Diagnosed Prevalent Population of MSA

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of MSA?
• What is the historical MSA patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of MSA at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to MSA?
• Out of the above-mentioned countries, which country would have the highest prevalent population of MSA during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The MSA report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM MSA epidemiology forecast.
• The MSA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The MSA epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Oral Mucositis - Epidemiology Forecast to 2030

  • $ 3750
  • February 2021
  • 96 pages

‘Oral Mucositis (OM) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted OM epidemiology in the 7MM, i.e., the United States, EU5 (Germany, ...

  • United States
  • Germany
  • Epidemiology
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on